263 related articles for article (PubMed ID: 20509860)
1. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
[TBL] [Abstract][Full Text] [Related]
2. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
Gallmeier E; Hucl T; Calhoun ES; Cunningham SC; Bunz F; Brody JR; Kern SE
Cancer Biol Ther; 2007 May; 6(5):654-60. PubMed ID: 17387268
[TBL] [Abstract][Full Text] [Related]
3. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC.
Taniguchi T; D'Andrea AD
Blood; 2002 Oct; 100(7):2457-62. PubMed ID: 12239156
[TBL] [Abstract][Full Text] [Related]
4. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
6. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
7. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
9. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.
Gordon SM; Alon N; Buchwald M
J Biol Chem; 2005 Oct; 280(43):36118-25. PubMed ID: 16127171
[TBL] [Abstract][Full Text] [Related]
10. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Gallmeier E; Hucl T; Brody JR; Dezentje DA; Tahir K; Kasparkova J; Brabec V; Bachman KE; Kern SE
Cancer Res; 2007 Mar; 67(5):2169-77. PubMed ID: 17332347
[TBL] [Abstract][Full Text] [Related]
12. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
Wilson JB; Johnson MA; Stuckert AP; Trueman KL; May S; Bryant PE; Meyn RE; D'Andrea AD; Jones NJ
Carcinogenesis; 2001 Dec; 22(12):1939-46. PubMed ID: 11751423
[TBL] [Abstract][Full Text] [Related]
13. A role for the Fanconi anemia C protein in maintaining the DNA damage-induced G2 checkpoint.
Freie BW; Ciccone SL; Li X; Plett PA; Orschell CM; Srour EF; Hanenberg H; Schindler D; Lee SH; Clapp DW
J Biol Chem; 2004 Dec; 279(49):50986-93. PubMed ID: 15377654
[TBL] [Abstract][Full Text] [Related]
14. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
17. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
18. Fanconi anemia protein complex: mapping protein interactions in the yeast 2- and 3-hybrid systems.
Gordon SM; Buchwald M
Blood; 2003 Jul; 102(1):136-41. PubMed ID: 12649160
[TBL] [Abstract][Full Text] [Related]
19. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of fanconi anemia.
Taniguchi T; Dandrea AD
Int J Hematol; 2002 Feb; 75(2):123-8. PubMed ID: 11939257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
